Evommune, Inc. (EVMN)
NYSE: EVMN · Real-Time Price · USD
21.90
-0.03 (-0.14%)
Dec 5, 2025, 4:00 PM EST - Market closed

Evommune Balance Sheet

Millions USD. Fiscal year is Jan - Dec.
Fiscal Year
TTM FY 2024 FY 2023
Period Ending
Jun '25 Dec '24 Dec '23
Cash & Equivalents
61.8416.2629.02
Short-Term Investments
24.9655.7950.06
Cash & Short-Term Investments
86.872.0479.08
Cash Growth
--8.91%-
Prepaid Expenses
6.61.950.95
Total Current Assets
94.973.9980.03
Property, Plant & Equipment
1.051.81.97
Other Long-Term Assets
0.270.270.25
Total Assets
96.2176.0682.25
Accounts Payable
3.678.261.76
Accrued Expenses
5.926.734.03
Current Portion of Leases
0.420.860.77
Current Unearned Revenue
-3-
Other Current Liabilities
0.089.130.3
Total Current Liabilities
10.0927.986.86
Long-Term Leases
0.350.520.49
Long-Term Deferred Tax Liabilities
--3
Other Long-Term Liabilities
-0.020.25
Total Liabilities
10.4428.5210.59
Common Stock
-00
Additional Paid-In Capital
9.117.986.2
Retained Earnings
-180.34-152.22-83.91
Total Common Equity
-171.23-144.24-77.71
Shareholders' Equity
85.7747.5471.66
Total Liabilities & Equity
96.2176.0682.25
Total Debt
0.771.381.26
Net Cash (Debt)
86.0270.6677.83
Net Cash Growth
--9.21%-
Net Cash Per Share
6.685.507.29
Filing Date Shares Outstanding
13.2513.2510.68
Total Common Shares Outstanding
13.2513.2210.68
Working Capital
84.846.0173.18
Book Value Per Share
-12.93-10.91-7.28
Tangible Book Value
-171.23-144.24-77.71
Tangible Book Value Per Share
-12.93-10.91-7.28
Source: S&P Global Market Intelligence. Standard template. Financial Sources.
SEC Filings: 10-K · 10-Q